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Transdermal delivery system bypass the hepatic first pass 
metabolism and avoid drug degradation due to gastrointestinal 
pH, enzymes etc., minimize plasma level fluctuations and 
extend the drug activity besides improving patient compliance. 
Transdermal films of metoprolol tartarate were prepared using 
polymers such as ethyl cellulose, poly vinyl alcohol, eudragit 
RL100, eudragit L100. Di-n-butylphlthalate was used as 
plasticizer. The study was undertaken to report the film 
forming properties of polymers used and in vitro drug release 
from the prepared monolithic matrices. Effect of drug loading 
on the drug release rate was also studied. The transdermal films 
were prepared using solvent casting method. These films were 
evaluated for Thickness, Percent moisture loss, Percent 
moisture absorption, Drug content, Weight variation and 
folding endurance. In-vitro drug release kinetics was studied 
using Franz-diffusion cell. Drug release followed zero order 
kinetics. Drug loading at different concentrations found to have 
less effect on the film forming properties of the constituent 
polymers. Results have shown enhanced flux per unit time 
across rat skin. In conclusion combination of ethyl cellulose, 
poly vinyl alcohol, eudragit RL100, eudragit L100 and Di-n-
butylphlthalate can potentially be optimized to develop an 
effective transdermal drug delivery system for metoprolol 
tartarate.  
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In recent years, considerable attention has been focused on the 
development of new drug delivery systems. Transdermal drug 
delivery system has been in existence for a long time. In past, 
the most commonly applied systems were topically applied 
creams and ointments for dermatological disorders. Drugs 
administered in the form of tablets, capsules, injectables and 
ointment etc., usually produce wide ranging fluctuation in drug 
concentrations in the blood stream and tissues and factors such 
as repetitive dosing and unpredictable absorption send lead to 
the concept of controlled drug delivery system or therapeutic 
system. 
Transdermal systems provide drug systemically at a predictable 
rate and maintain the rate for extended periods of time thus 
eliminating numerous problems associated with oral products 
such as unpredictable or reduced bioavailability, enhanced first 
pass hepatic metabolism, relatively short residence time, dose 
dumping and dosing inflexibility 
Metoprolol tartrate is a beta blocker used in the treatment of 
hypertension, undergoes hepatic first pass metabolism 
reductions in low bioavailability 40-50% given by oral route 
and the low dose (100 -200mg) daily.  Hence it is suitable for 
formulation as a transdermal patch.The present study was 
undertaken to formulate the matrix type transdermal patches of 
metoprolol tartarate. The polymers used for the preparation of 
monolithic matrix were Ethyl Cellulose (EC), Poly Vinyl 
Alcohol (PVA), Eudragit RL100, Eudragit L100 and Di-n-
butylphlthalate used as plasticizer. The investigations intend to 
report the film forming properties of the selected polymers and 
also to study in-vitro drug release from the prepared 
transdermal
 patches across the freshly excised rat skin. 
MATERIALS AND METHODS 
Metoprolol tartarate was obtained as the gift sample from the 
Madras Pharmaceuticals Ltd, Chennai. Ethyl Cellulose, 
Eudragit RL100; Eudragit L100 was obtained as the gift 
sample from the Glenmark pharmaceutical Ltd, Mumbai. Di-n-
butylphlthalate and poly vinyl alcohol purchased from the local 
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vendors. Apart from these all other chemicals used were analytical grade reagents. 
Table 1: Composition of Transdermal Patches 







F1 - 5 5 - 0.12gm 
F2 4.5 - - 5.5 0.12gm 
F3 4 2 3 1 0.12gm 
F4 2 1.5 2.5 4 0.12gm 
F5 3.5 - 6.5 - 0.12gm 
Experimental 
Preparation of monolithic matrix films 
The matrix type transdermal patches containing metoprolol 
tartrate prepared using different ratios of Eudragit RL100 and 
Eduragit L100. The polymers in different ratios were increased 
to a total weight of 400 mg and dissolved in phosphate buffer 
pH 7.4. Metoprolol tartrate (50 mg) was added slowly to the 
polymer solution and mixed thoroughly to obtain a uniform 
solution. Di-n-butyl-phthalate was used as a plasticizer. The 
polymeric solution of the drug was poured onto the mercury 
surface (25cm2) and dried at room temperature in dust free 
environment. After 24 hours the film were cut into a pieces of 
5cm2 area and a backing membrane of aluminum foil was 
glued on. The transdermal films were stored in desiccator until 
further use.  
Evaluation of the films 
The evaluation of the films was performed for the Thickness, 
Percent moisture loss, Percent moisture absorption, Drug 
content, Folding endurance, Weight variation 
Thickness  
Thickness of the films was measured at six different points 
using a screw gauge and average thickness of three films was 
found out.  
Percent moisture absorption 
The percent moisture absorption test was carried out to check 
the physical stability and integrity of the films at high humid 
conditions. In the present study the moisture absorption 
capacities of the films were determined in the following 
manner. 
The films were placed is desiccator containing saturated 
solution of aluminum chloride, keeping the humidity inside the 
desiccator at 79.5% RH. After 3 days the films were taken and 
weighed the percentage moisture absorption of three films was 
found.  





Percent Moisture Loss 
This test was also carried to check the integrity of 
films at dry condition. Three films of 5 square centimeter area 
was cut and weighed accurately and kept in a desiccator 
containing fused anhydrous calcium chloride.  
After 72 hours the films were removed and weighed. 
Average percentage moisture loss of three films was found out.  
 
Percent moisture loss =   Initial weight-Final weight    X 100 
                                                       Initial weight 
    
Drug Content 
A film of 5 square centimeter area was cut and dissolved in 
phosphate buffer. After adding suitable reagent and dilution, 
optical density was found out at 223nm. Average drug content 
of three transdermal films were determined.  
Folding Endurance  
It was determined by repeatedly folding a small strip of films at 
the same place till it broke. The number of times, the films 
could be folded at the same place without breaking gave the 
value of folding endurance.  
Weight Variation 
Each film was weighed individually and average weight of 
three films was found. 
In-Vitro Dissolution Studies 
In-vitro dissolution studies were carried out in phosphate buffer 
pH 7.4 for 24 hours. In order to find out the order of release 
and the mechanism, which was predominantly influences the 
drug release from membrane, the in-vitro drug dissolution data 
was subjected to the different modes of graphical treatment. 
Percentage cumulative drug release vs time 
 




Ex-Vivo Permeation Studies  
Male rats weighting 105 – 120 gm free from any visible sign of 
disease were selected.  Having a depilatory preparation hair 
removed from the skin of full thickness was excised from the 
rat.  This was mounted on the donor compartment. The 
Transdermal patch was placed over it.   
The permeation study was carried out in the similar manner as 
that with artificial membrane   
RESULTS AND DISCUSSION 
In the present study efforts were to prepare transdermal patches 
of Metoprolol tartrate by using different polymers in different 
ratios such as Eudragit RL100, Eudragit L100, PVA and EC 
using different combinations of the above mentioned polymers 
and the plasticizer used dibutyphthalate.  
The prepared formulations were subjected to various 
physiochemical characteristics such as percent moisture 
absorption, percent moisture loss, drug content, thickness, 
folding endurance and weight variation. The release 
characteristics of formulation were studied in-vitro dissolution 
studies Ex-vivo studies by using of rat skin.  
The formulation F1 has shown the highest percent moisture 
absorption and percent moisture loss than other formulation. 
This might be because of the high water permeability of. It also 
observed that formulation F3 has shown least percent moisture 
absorption and percent moisture loss which might be due to the 
low permeability of Eudragit RL 100 to water.  
The thickness of the films varied from 16 to 21mm.  The 
minimum standard deviation values assumed that the process 
used for preparing the drug delivery system is capable of 
giving reproducible result. This fact is further conformed by 
drug content and weight uniformity studied. In order to 
evaluate the flexibility the film were subjected to folding 
endurance studied.  The values in the range that prepared films 
were observed batches having capability to withstand the 
mechanical pressure along with good flexibility.  
The formulations F1, F2, F3, F4and F5 have shown the drug 
release for 24 hours to the extent of 99%, 99.04%, 78.08%, 
81.84% and 91.04% respectively. The Higuchi’s plot has 
shown the regression value of five formulations in Table 2 
which indicates that the release of drug from the patch was 
governed by a diffusion mechanism.  
Table 2: Regression Values of Formulations 
 
























































Cumulative % of 
Drug release  
(F1) 
Cumulative % of 
Drug release  
(F2) 
Cumulative % of 
Drug release (F3) 
Cumulative % of 
Drug release  
(F4) 
Cumulative % of 
Drug release  
(F5) 
1. 67.2 53.52 29.52 23.36 50.4 
2. 68.24 54.08 30.08 25.5 51.04 
3. 68.8 55.35 30.72 27.04 52.24 
4. 70.4 56.0 32.0 29.52 53.52 
5. 72.8 57.2 33.84 33.2 54.72 
6. 75.0 58.4 36.24 35.04 56.0 
7. 80.0 60.24 38.08 36.24 57.2 
8. 81.2 67.2 40.0 40.0 59.04 
9. 81.8 68.88 42.4 42.4 60.88 
10. 83.6 70.08 45.52 44.88 65.2 
11. 84.8 72.0 48.56 46.72 67.04 
12. 85.5 72.0 49.84 48.86 70.72 
13 86.0 72.8 52.24 51.68 72.0 
14 89.2 76.24 53.52 53.52 72.8 
15. 91.0 78.08 54.72 54.72 75.2 
16. 91.6 84.0 57.2 57.2 78.08 
17. 92.2 85.52 59.68 59.68 79.3 
18. 93.5 88.56 62.72 60.88 82.4 
19. 95.3 91.68 65.84 65.54 84.24 
20 95.3 92.88 67.04 68.88 85.52 
21 96 94.72 70.08 72.0 86.08 
22 96.5 99.04 72.0 74.4 87.36 
23. 97.2 99.04 75.04 77.52 88.56 











Formulation F3 containing was found to best among all batches 
because of its consistent release rate for 24 hour and extent of 
drug release was 78.08%. 
Ex-vivo permeating studied confirmed that in-vitro drug 
release data corrected with the ex-vivo data observed in rat 
skin. 
The formulation F3 has achieved the object to extended release 
reduced frequency of administration, avoids the first pass effect 
and thus may improve the patient compliance.  
As the extension of work pharmacokinetic studies, in-vivo 
studies on higher animals and controlled clinical studies on 
human being can be carried out in future.  
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